Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)
"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
Spotlight: Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring (in mice)
"we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period"
Spotlight: The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry (Soylemez, et al, 2025)
"These compounds have been shown to enable access to unconscious cognitive and emotional content, facilitate emotional release, and induce a temporary dissolution of ego boundaries—processes that may underpin significant and enduring therapeutic outcomes."
Spotlight: Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis (Landrum, et al, 2025)
" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. "
Spotlight: Charting a New Frontier: Integrating Cognitive Behavioral Therapy Approaches with 3,4-methylenedioxymethamphetamine (MDMA)
"Psychedelics are being integrated with established cognitive behavioral therapies (CBTs).MDMA is a focus of recent research of psychedelic-assisted cognitive behavioral therapy.Six papers explore interesting and important questions on how to leverage the potential of psychedelics to augment CBTs."
Spotlight: Ketamine's Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review (Silva, et al, 2025)
"Our findings indicate that ketamine reduces excitotoxicity and inflammation, which may contribute to neuroprotection in acute neurological injuries. These insights underscore ketamine's potential as an adjunctive neuroprotective agent, warranting further clinical investigation...